Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SOLVE

Financiado

Cerrado

Sustainable COVID-19 Vaccination for Long-term Vaccine Immunity and Effectivenes...

Sustainable COVID-19 Vaccination for Long-term Vaccine Immunity and Effectiveness Despite the rapid development of various SARS-CoV-2 vaccines, the control of the pandemic is hampered by the constant emergence of SARS-CoV-2 variants escaping vaccine-induced immunity and the waning of immunity. SOLVE will tackle... ver más

31/12/2028

INSERM

9M€

Presupuesto del proyecto: 9M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-08

HORIZON-HLTH-2023-DISEASE-03-17: Pandemic preparedness and response:... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

INSERM

2.91M€ | Lider

CEA

1.99M€ | Participante

swiss aeropole SA

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PTQ2021-011651 Estudio sistemático de los mecanismos celulares implicados e... 70K€ Cerrado

CoVICIS EU-Africa Concerted Action on SAR-CoV-2 Virus Variant and Im... 10M€ Cerrado

PROACTIVE PROposing Action to ConTrol and Impede betacoronaVirus Emerg... 2M€ Cerrado

PDC2021-121307-I00 IMPACTO DEL VECTOR MVA-ISG15 EN LA INFECION POR SARS-COV-2/C... 150K€ Cerrado

EAVI2020 European AIDS Vaccine Initiative 2020 24M€ Cerrado

ADITEC Advanced Immunization Technologies 41M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-12-08
Fecha Fin: 2028-12-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 9M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite the rapid development of various SARS-CoV-2 vaccines, the control of the pandemic is hampered by the constant emergence of SARS-CoV-2 variants escaping vaccine-induced immunity and the waning of immunity. SOLVE will tackle these challenges by deciphering the mechanisms of induction of long-lasting immunity and evaluating new vaccine platforms. To achieve this goal, an integrated plan has been developed including six pillars: 1) Vaccine discovery and design; 2) Head-to-head evaluation of the immune response and long-lasting immunity induced by four vaccine platforms in the preclinical setting; 3) Validation of the pre-clinical results in an experimental medicine trial (EMT); 4) Immune mechanisms of long-lasting immunity; 5) Data Science; 6) Determinants of population adherence to vaccination. New immunogens including key mutations from most recent variants in RBD and Nucleocapsid sequences highly conserved across Sarbecoviruses, will be delivered through: antigen-targeting to dendritic cells (DC), i.e., CD40 DC-targeting, nanoparticles, a MVA vector and 2nd generations of mRNAs. SOLVE will evaluate in depth the immunogenicity of these vaccines in the preclinical setting, and in an EMT testing two vaccines, i.e., CD40 DC-targeting and MVA with available GMP clinical lots. SOLVE will benefit from the most advanced technologies to identify the mechanisms of long-lasting immunity. Integrative analyses of high throughput data, including from large cohorts, will provide insights for identification of factors (demographics, vaccines, immunity) which impact quality and longevity of immunity. SOLVE will investigate stakeholders’s perspective on the acceptability of large vaccination campaigns to improve implementation of next generation of vaccines in a preparedness track. The consortium gathers 8 renowned public/private institutions supported by a governance facilitating fast sharing of information to keep up with a tight schedule imposed by the pandemic.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores